We distribute our research widely to institutional and retail investors through various channels, including our proprietary database, website, and other platforms (such as Bloomberg, Thomson Reuters and Factset).

We are fully MiFID II compliant. Our research is paid for by our corporate clients, and we do not carry out any execution business.

Published reports can be obtained by searching our Research Library below, or directly from the relevant Company Pages.

Advanced search
Date range (dd-mm-yyyy)

Redx Pharma

Momentum and execution continue in H121

Update | 08 June 2021

Futura Medical

Raising £12m through £10m placing and £2m retail offer

Lighthouse | 17 May 2021

Nexstim

Consolidating both shares and strategy

Update | 12 May 2021

ANGLE

Parsortix commercial traction would be transformational

Initiation | 11 May 2021

Allergy Therapeutics

G309 exploratory grass trial on course for H221 read-out

Lighthouse | 06 May 2021

Futura Medical

MED3000 receives CE Mark as a Class II(b) device

Lighthouse | 30 April 2021

MaxCyte

Catching an unbroken wave

Update | 27 April 2021

Futura Medical

FY21 is set to be a year of execution

Update | 14 April 2021

HUTCHMED

Baring Private Equity Asia invests $100m

Lighthouse | 08 April 2021

Nexstim

Rights issue 178% oversubscribed

Lighthouse | 08 April 2021
1 2 3 4 5 6 7 8 9 10 >
248 results found.